



# Drug Discovery 2017

ACC, LIVERPOOL

3<sup>rd</sup> - 4<sup>th</sup> October 2017

## INNOVATIONS IN ASSAY DESIGN, DEVELOPMENT AND SCREENING Tuesday 3<sup>rd</sup> October 2017: ROOM 3

### Session Chairs

**Helen Boyd** (AstraZeneca) & **Florian Fuchs** (Novartis)

Over the past 5 years the screening landscape to find tools and hits has changed dramatically as new assay technologies step into the limelight. No longer are screens run using simple reads outs, but are more often multi-parametric in nature and generate large volumes of data. This evolution to more disease relevant assays and screens has been observed mostly in the area of cell based assays as imaging becomes the “norm” along with the use of transcriptomics and precise genome editing.

Alongside this change the types of cells and cellular systems being used in screening has moved away from recombinant cell lines and this presents both opportunities and challenges in terms of the assay development plus the scale and outcome of a screen. The other dimension which is changing concerns the growing number of new modalities in drug discovery alongside traditional small molecules. In this session we would like to give you a flavor of many of these new and exciting areas.

### CONFIRMED SPEAKERS

**Christoph Dumelin** (Novartis)

**Christoph Bock** (CeMM Research Center for Molecular Medicine)

**Olivier Frey** (ETH Zurich)

**Helena Peilot** (AstraZeneca)

**Ali Tavassoli** (University of Southampton)

**Joanne Shearer** (Charles River Cambridge)

Follow us on Twitter [@ELRIG\\_UK](https://twitter.com/ELRIG_UK) for all the latest updates on ELRIG events & news.

[www.elrig.org](http://www.elrig.org)